C-X-C motif chemokine 6

Also known as: Chemokine alpha 3, Granulocyte chemotactic protein 2, Small-inducible cytokine B6, CXCL6, P80162

**Mechanism of Action** C-X-C motif chemokine 6 (CXCL6), also known as granulocyte chemotactic protein 2 (GCP-2), is a member of the CXC chemokine family. It exerts its biological effects primarily by binding to the chemokine receptors CXCR1 and CXCR2, which are expressed on the surface of neutrophil granulocytes. This interaction triggers intracellular signaling cascades, including activation of the MAPK and PI3K pathways, leading to directed chemotaxis, degranulation, and respiratory burst in neutrophils. CXCL6 also promotes angiogenesis and tissue remodeling through its effects on endothelial cells. **Key Research Findings** Preclinical studies have demonstrated that CXCL6 is upregulated in inflammatory conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease, and bacterial infections, where it amplifies neutrophil recruitment to sites of tissue damage. Elevated CXCL6 levels correlate with disease severity in sepsis and inflammatory bowel disease models. Conversely, CXCL6 blockade reduces neutrophil infiltration and tissue injury in murine models of acute lung injury and arthritis. Limited evidence also suggests a role in tumor progression, as CXCL6 expression in certain cancers (e.g., colorectal, pancreatic) is associated with enhanced angiogenesis and metastasis. **Clinical Relevance** CXCL6 remains an experimental target with no approved clinical applications. Its potential as a therapeutic target lies in modulating neutrophil-driven inflammation, particularly in chronic inflammatory and autoimmune diseases. However, the redundancy of the chemokine system (overlapping functions with CXCL8/IL-8) and the risk of immunosuppression pose challenges. Current research focuses on developing selective CXCR1/2 antagonists and evaluating CXCL6 as a biomarker for disease activity. For research purposes only — not medical advice.

Key data

Mechanism of action

Chemotactic for neutrophil granulocytes. Signals through binding and activation of its receptors (CXCR1 and CXCR2). In addition to its chemotactic and angiogenic properties, it has strong antibacterial activity against Gram-positive and Gram-negative bacteria (90-fold-higher when compared to CXCL5 and CXCL7)

Research & studies

Frequently asked questions

Related peptides